Literature DB >> 12667426

Targeting CD36: modulating inflammation and atherogenesis.

David P Hajjar1, Antonio M Gotto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12667426     DOI： 10.1007/s11883-003-0016-z

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


× No keyword cloud information.
  4 in total

Review 1.  CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism.

Authors:  M Febbraio; D P Hajjar; R L Silverstein
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

2.  Lovastatin inhibits gene expression of type-I scavenger receptor in THP-1 human macrophages.

Authors:  N Umetani; Y Kanayama; M Okamura; N Negoro; T Takeda
Journal:  Biochim Biophys Acta       Date:  1996-10-18

3.  Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells.

Authors:  A Pietsch; W Erl; R L Lorenz
Journal:  Biochem Pharmacol       Date:  1996-08-09       Impact factor: 5.858

4.  Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes.

Authors:  Bianca Fuhrman; Lena Koren; Nina Volkova; Shlomo Keidar; Tony Hayek; Michael Aviram
Journal:  Atherosclerosis       Date:  2002-09       Impact factor: 5.162
  4 in total
  2 in total

1.  Genome-wide analysis of YY2 versus YY1 target genes.

Authors:  Li Chen; Toshi Shioda; Kathryn R Coser; Mary C Lynch; Chuanwei Yang; Emmett V Schmidt
Journal:  Nucleic Acids Res       Date:  2010-03-09       Impact factor: 16.971

Review 2.  Inflammation at the molecular interface of atherogenesis: an anthropological journey.

Authors:  Brian D Lamon; David P Hajjar
Journal:  Am J Pathol       Date:  2008-11       Impact factor: 4.307
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.